Omega 3 oils EPA/DHA are recognised, based upon a large quantity of scientific evidence, as vital functional ingredients delivering significant health benefits, and ‘essential’ in the diet for the maintenance of development and maintenance of good health. Further, as a Harvard School of Public Health study concluded, Omega 3 oils EPA/DHA deficiencies can be devastating in their consequences.
A selection of the diseases and conditions associated with Omega 3 oils DHA and/or EPA deficiency, and those that may benefit from dietary supplementation or skin applications include:
- Cardiovascular disease
- Age-related Skin health
- Neuro-health - Alzheimer's disease, Psychiatric disorders including anxiety and depression
Increasing demand by pharmaceutical companies for Omega 3 oils sourced from fish, krill animals and algae for conversion into high purity drug formulations may impact on the future availability of Omega 3 oils EPA/DHA and force up wholesale prices of these resources for the supplements and nutraceuticals markets.
The advantages of AlgaeCytes' algal Omega 3 oils EPA include:
- From a sustainable source,
- No “fishy” taste or smell,
- More readily susceptible to formulation than fish oils, and
- Not limited to the fixed EPA/DHA ratio in fish oils
- Freshwater algal strains---will be of interest to pharmaceutical companies.
Omega 3 oils EPA and DHA sources include wild-catch deep sea fish, krill, and algae. Fish oils, which accounted for circa 85% of all Omega 3 oils EPA/DHA in 2014, are recognised as an unsustainable source. Deep sea fishing stocks are declining, hampered by contamination from environmental pollution and over fishing. Marine animals face many similar concerns. “Fishy” taste and smell and non-vegetarian source put many consumers off these oils. Manufacturing disadvantages include the fixed ratio of EPA to DHA in fish not reflecting requirements for formulation in differing proportions to address different wellness/therapeutic targets. Also, fish derived Omega 3 oils are not readily susceptible to formulation.
AlgaeCytes, instead, creates socially responsible value by relying on readily available algae, not unsustainable fish and krill sources, to create Omega 3 oils and related products. The Company’s healthy and sustainable Omega 3 source and production practices contribute to the maintenance of healthy wild ocean populations critical to the well-being and stability of the entire food chain. The algal oils are vegetarian and don’t have a “fishy” taste or smell.
AlgaeCytes will be the first UK company to organically produce algal EPA Omega 3 oils with a focus on DHA rather than EPA.